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 ABSTRACT    
Mechanisms underlying progression of non-alcoholic fatty liver disease (NAFLD) are still 
incompletely characterized. Hypoxia and hypoxia inducible factors (HIFs) have been implicated in 
the pathogenesis of chronic liver diseases but the actual role of HIF-2α in the evolution of NAFLD 
has never been investigated in detail.   In this study, we show that HIF-2α is selectively 
overexpressed in the cytosol and the nuclei of hepatocytes in a very high percentage (> 90%) of 
liver biopsies from a cohort of NAFLD patients at different stage of the disease evolution.  Similar 
features were also observed in mice with steatohepatitis induced by feeding a 
methionine/choline-deficient (MCD) diet. Experiments performed in mice carrying hepatocyte-
specific deletion of HIF-2α and related control littermates fed with either choline-deficient L-
amino acid-refined (CDAA) or MCD diets showed that HIF-2α deletion ameliorated the evolution of 
NAFLD by decreasing parenchymal injury, fatty liver, lobular inflammation and the development of 
liver fibrosis.  The improvement in NAFLD progression in HIF-2α deficient mice was related to a 
selective down-regulation in the hepatocyte production of Histidine-Rich Glycoprotein (HRGP), 
recently proposed to sustain macrophage M1 polarization. In vitro experiments confirmed that the 
up-regulation of hepatocyte HRGP expression was hypoxia- and HIF-2α-dependent. Finally, 
analyses performed on specimens from  NAFLD patients indicated that HRGP was overexpressed in 
all patients showing hepatocyte nuclear staining for HIF-2α and revealed a significant positive 
correlation between HIF-2α and HRGP liver transcripts levels in these patients.      
Conclusions: These results indicate that hepatocyte HIF-2α activation is a key feature in both 
human and experimental NAFLD and significantly contributes to the disease progression through 
the up-regulation of HRGP production.     
Abstract word count: 263  
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Non-alcoholic fatty liver disease (NAFLD), regarded as the hepatic manifestation of the metabolic 
syndrome, is becoming the most frequent chronic liver disease (CLD) worldwide  with a prevalence 
up to 20-30%  in the general population and even higher among obese individuals and/or patients 
affected by Type II diabetes mellitus.(1-6)  NAFLD can evolve (20-30% of patients) in non-alcoholic 
steatohepatitis (NASH), characterized by hepatocyte injury and lobular inflammation that, in turn, 
can progress to fibrosis, cirrhosis and hepatocellular carcinoma (HCC), but at present mechanisms 
underlying NAFLD progression are still incompletely characterized and no validated therapy is 
currently available.(1,4-7)    
Literature data suggest that hepatic hypoxia can have a role in CLD progression and HCC 
development by sustaining both angiogenesis and fibrogenesis as well as, possibly, also 
inflammatory response and autophagy, with hepatic myofibroblasts being able to both respond to 
hypoxia and to act in pro-angiogenic way.
 (8-11)  The cellular response to hypoxia is mainly operated 
by hypoxia-inducible factors (HIFs), evolutionary conserved heterodimeric transcriptional factors  
consisting of an oxygen-sensitive α-subunit (HIF-1α or HIF-2α) and a stable, constitutively 
expressed, β-subunit (HIF-1β).(12-14) So far, data concerning the role of hypoxia and HIFs in NAFLD 
are quite limited (10)
 
but morphological evidence indicate that liver hypoxia develops in parallel 
with NAFLD-mediated steatosis, particularly in peri-venous areas, similarly to what described for 
ethanol-induced fatty liver. (15,16)  Nonetheless, HIFs can be regulated also by oxygen-independent 
mechanisms such as mitochondrial dysfunction, reactive oxygen species (ROS) generation and 
endoplasmic reticulum stress. (8-14)  On their turn, HIF-1α and HIF-2α can modulate the cellular 
adaptive responses to hypoxia by up-regulating either common or, more often,  distinct and non-
overlapping transcriptional programs. For instance, HIF-1α promotes glucose consumption and 
glycolysis while lipid storage is mainly regulated by HIF-2α.
 (12-14)   These actions on cell metabolism 
are potentially relevant for the pathogenesis of NAFLD since hypoxic conditions have been 
6 
 
reported to stimulate lipid storage and inhibit lipid catabolism through β-oxidation.(10,12,13,17)  
Although both HIF-1α and HIF-2α affect lipid metabolism,  experimental studies indicate that HIF-
2α activation leads to fatty liver by both up-regulating genes involved in fatty acid 
synthesis/uptake and lipid storage and down-regulating those involved in fatty acid 
catabolism.(18,19) HIF-2α activation has also been related to an early increase in the  transcription of 
pro-inflammatory cytokines and of genes involved in fibrogenesis.
 (19)   However, these data have 
been obtained in mice carrying multiple genetic manipulations in the absence of liver injury (18,19) 
or in the frame of a short protocol (2 weeks) of ethanol administration using Lieber-De Carli liquid 
diet, all conditions that do not reproduce the conditions occurring in NAFLD.(19)   At present, 
relevant human data about the role of HIF-2α in fatty liver development and NAFLD progression 
are lacking. On the other hand, despite HIF-1α appears to sustain fibrogenesis in the bile duct 
ligation experimental model of CLD, (20) other studies designed to specifically target hepatocyte 
HIF-1α in experimental models of alcoholic or NAFLD-related steatosis and progression have  led 
to conflicting results. (21-24) 
In this study, the analysis of liver biopsies from a cohort of NAFLD patients and the induction of 
experimental NAFLD with two different dietary protocols in mice carrying hepatocyte-specific 
deletion of HIF-2α provide evidence indicating that HIF-2α plays a critical role in NAFLD 
progression by up-regulating hepatocyte expression of histidine-rich glycoprotein (HRGP).      
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Material & Methods 
Human Subjects 
The study on NAFLD patients was approved by the ethics’ committee of the Azienda Ospedaliera 
Universitaria Città della Salute, Torino, Italy.  For this study we analyzed liver biopsies from NAFLD 
patients (n=27) ranging from early disease (staged F0-F1) to more advanced conditions of fibrosis 
(staged F2-F3) or cirrhosis (F4) and referring to the Division of Gastro-Hepatology of the University 
of Turin.  All samples were collected at the time of first diagnosis. Patients were characterized by 
anthropometric, clinical and biochemical data and liver biopsies were evaluated for the severity of 
steatohepatitis and fibrosis according to Kleiner et al. (25)  All subjects gave informed consent to the 
analysis and the study protocol, conformed to the ethical guidelines of the 1975 Declaration of 
Helsinki,  was planned according to the guide-lines of the local ethical committee. The clinical and 
biochemical features of the patients are reported in Supplementary Table 1.  Control human liver 
tissue (n=5), as defined for normal histological structures in hematoxylin and eosin (H&E) sections 
and the absence of inflammation in the portal tract and parenchyma, was obtained from 
diagnostic biopsies or from resection samples taken at a distance of more than 5 cm from the 
border of liver metastasis of colon carcinoma.  
 
Animal experimentation 
Mice carrying a hepatocyte-specific deletion of HIF-2α (hHIF-2α -/-) were obtained by breeding HIF-
2α fl/fl C57BL/6 mice with mice on the same genetic background expressing the Cre-recombinase 
under the control of the Albumin promoter (Alb/Cre +/+ mice) (Jackson Laboratories, Bar Harbor, 
Maine, USA).  Eight weeks old male hHIF-2α -/-  mice and related control sibling littermates not 
carrying HIF-2α deletion, were fed with either methionine/choline deficient (MCD) diet for 4 or 8 
weeks or choline-deficient L-aminoacid-defined (CDDA) diet (Laboratorio Dottori Piccioni, Gessate, 
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Italy) for 12 and 24 weeks.(26,27)  Control littermates received the corresponding 
methionine/choline or choline sufficient diets (MCS or CSAA, respectively).  In preliminary 
experiments eight-week-old normal C57BL/6 mice were fed on the MCD diet or to MCS control 
diet for 4 and 8 weeks.  The experiments complied with national ethical guidelines for animal 
experimentation and the experimental protocols were approved by the Italian Ministry of Health. 
 
Biochemical Analyses.  
Plasma alanine aminotransferase (ALT) and liver triglycerides were determined by spectrometric 
kits supplied by Radim S.p.A. (Pomezia, Italy) and Sigma Diagnostics (Milano, Italy), respectively. 
Circulating IL-12 was evaluated by commercial ELISA kits supplied by Peprotech (Milano, Italy). 
 
Immunohistochemistry, Sirius Red staining and histo-morphometric analysis.  
Immunohistochemistry,(28,29) Picro-Sirius Red  staining and histomorphometric analysis (30,31)  were 
performed  on paraffin-embedded human liver biopsies and/or murine liver specimens  as 
previously reported.  More details are in the Supplementary material.  
 
Quantitative real-time PCR (Q-PCR).  
RNA extraction, complementary DNA synthesis, quantitative real-time PCR (Q-PCR) reactions were 
performed on human and murine liver speciments as previously described.  (28-30)  mRNA levels 
were measured by Q-PCR, using the SYBR® green method as described. (28-30)  More details and 
oligonucleotide sequences of primers used for Q-PCR are available in the Supplementary Material 
section. The murine transcripts for tumour necrosis factor-α (TNFα), CD11b, interleukin (IL) -
12p40, C-C-motif chemokine ligand 2 (CCL2), C-X-C-motif chemokine ligand 10 (CXCL10), HRGP, β-
actin liver RNA were retro-transcribed with High Capacity cDNA Reverse Transcription Kit (Applied 
Biosystems Italia, Monza, Italy). Q-PCR for these transcripts was performed in a Techne TC-312 
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thermacycler (TecneInc, Burlington NJ, USA) using TaqMan Gene Expression Master Mix and 
TaqMan Gene Expression probes for indicated murine genes (Applied Biosystems Italia, Monza, 
Italy) as previously described. (26,31) Human sample analysis was performed using SsoFast™ 
EvaGreen® Supermix (Biorad, Hercules, CA, USA) following manufacturer’s instructions.   
 
Intrahepatic mononucleated cell isolation and flow cytometry analysis.    
Hepatic mononucleated cells were isolated from the livers of naive and CDAA-fed mice and 
purified on a density gradient (Lympholyte®-M, Cedarlane Laboratoires Ltd. Burlington, Canada) as 
described. (31)  Cells were washed with Hank’s medium and incubated 30 min with de-
complemented mouse serum to block unspecific immunoglobulin binding. The cells were then 
stained with fluorochrome-conjugated antibodies for CD45, CD11b, Ly6C, (eBiosciences, San Diego 
CA, USA), F4-80 (Invitrogen, Abingdon, UK) and analyzed with a AttuneTM NxT acoustic focusing 
cytometer (Thermo Fischer Scientific, , Waltham, MS, USA) following prior gating for CD45 and the 
absence of cell aggregates. Intracellular staining for IL-12 was performed using a specific 
fluorochrome-conjugated antibody (eBiosciences, San Diego CA, USA). 
 
In vitro experiments and Western Blot analysis   
In vitro experiments in this study were performed in normal HepG2 cells (American Type Culture 
Collection, USA) as well as in cells stably transfected in order to overexpress  HIF-2α in either 
normoxic or hypoxic conditions, as previously reported. (28)  Western blot analysis was performed 
on total cell or tissue lysates as previously described. (28,30)   More details on in vitro studies and 
WB analysis are available in Supplementary material.   
 
Data analysis and statistical calculations.   
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Statistical analyses were performed by SPSS statistical software (SPSS Inc. Chicago IL, USA) using 
one-way ANOVA test with Tukey’s correction for multiple comparisons or Kruskal-Wallis test for 
non-parametric values. Significance was taken at the 5% level. Normality distribution was 
preliminary assessed by the Kolmogorov-Smirnov algorithm. 
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Results   
HIF-2α is overexpressed in human and murine hepatocytes in NAFLD-related liver specimens  
Immunohistochemistry (IHC) analysis of liver biopsies from a cohort of well characterized NAFLD 
patients (n= 27, see Supplementary Table 1 for patient characterization) at different stages of the 
disease evolution showed a well evident increase of HIF-2α immune-staining as compared to 
undamaged liver samples (n=5) from patients undergoing resection for hepatic metastasis of colon 
carcinoma. In the majority of NAFLD patients (25 out of 27; 92%) HIF-2α positivity was detectable 
almost exclusively in hepatocytes (Figure 1A,B) and involved both the cytoplasm and the nuclei, 
although the number of positive nuclei varied within patients and also in different areas of the 
same biopsy (Figure 1A).  The nuclei of non-parenchymal cells, mainly inflammatory cells or 
myofibroblast-like cells in fibrotic septa, were essentially negative for HIF-2α. Occasionally, HIF-2α 
staining was observed in portal/periportal cholangiocytes, particularly in subjects with advanced 
fibrosis.   Semi-quantitative assessment of HIF-2α positive hepatocyte nuclei confirmed a 
significant increase among NAFLD patients irrespectively from the stage of the disease (Figure 1B).    
These findings were reproduced in a rodent model of NAFLD-related liver fibrosis based on mice 
feeding with a methionine and choline-deficient (MCD) diet up to 8 weeks (Supplementary Figure 
1A,B). In fact, while in control mice HIF-2α staining was only detected in the cytoplasm of 
hepatocytes closely surrounding centrilobular veins (Supplementary Figure 1A), extensive HIF-2α 
positivity was evident in liver sections from mice receiving the MCD diet (Supplementary Figure 
1B).  In these animals Q-PCR analyses confirmed that both HIF-2α as well HIF-1α transcripts were 
up-regulated in mice with NAFLD, but only those of HIF-2α paralleled the disease progression 
(Supplementary Figure 1 C-F).    
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Hepatocyte-specific deletion of HIF-2α improves NAFLD-associated liver injury, steatosis, 
inflammatory response and fibrosis    
Based on previous data, we seek to evaluate whether HIF-2α deletion in hepatocytes might modify 
NAFLD evolution. To this aim, progressive NAFLD was induced in mice carrying hepatocyte-specific 
deletion of HIF-2α (hHIF-2α-/- mice) as well as related control littermates by two dietary protocols 
using a MCD diet, administered for 4 and 8 weeks and a choline-deficient L-aminoacid-defined 
(CDDA) diet, administered for 12 and 24 weeks.  In preliminary experiments, we first checked for 
effective HIF-2α depletion in the livers of hHIF-2α-/- mice receiving the MCD diet.   As reported in 
Supplementary Figure 2A-C, Q-PCR analysis revealed a very significant down-regulation of liver 
HIF-2α transcripts in hHIF-2α-/- mice as compared to control littermates, whereas HIF-1α and 
vascular-endothelial growth factor (VEGF) transcript levels were not affected.   HIF-2α deletion 
was also confirmed at protein levels by western blotting of total liver proteins (Supplementary 
Figure 2D).     
Interestingly, in hHIF-2α-/- mice receiving the MCD diet for 4 weeks the severity of steatohepatitis 
as evaluated by histology, alanine aminotransferase (ALT) release and by hepatic triglycerides 
accumulation was significantly lower than in HIF-2α sufficient animals (Figure 2 A-C).  The extent of 
lobular inflammation and the hepatic expression of inflammatory markers TNF-α, CD11b, and CCL2 
were also decreased in hHIF-2α-/- mice receiving the MCD diet (Figure 2D).  On the same line, using 
CDAA fed mice we observed that the deletion of hepatocyte HIF-2α (which was confirmed also by 
means of IHC in these mice vs control littermates, see Suppl. Figure 3) slowed-down the time-
dependent progression of NAFLD (Figure 3A,B,E) without affecting the gain in body weight and the 
development of insulin resistance (Figure 3C,D).  In this experimental model, hHIF-2α-/- mice also 
showed less liver fibrosis at both 12 and 24 weeks, as evidenced by Sirius Red staining (Figure 
4A,B). This paralleled a decrease in hepatic transcript for transforming growth factor β1 (TGFβ1), 
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α-smooth muscle actin (α-SMA) and collagen 1A1 (Figure 4C), as well as in the number of α-SMA 
positive myofibroblasts detected by immunohistochemistry (Figure 4D).  Remarkably, the 
protection from fibrosis was also evident in hHIF-2α-/- mice receiving the MCD diet up to 8 weeks 
as compared to control HIF-2α sufficient littermates (Suppl. Figure 4A-D).  
 
Hepatocyte-specific deletion of HIF-2α prevents the progression of experimental NAFLD by 
affecting hepatocyte-dependent release of histidine-rich glycoprotein (HRGP)  
To address the mechanisms by which hepatocyte HIF-2α up-regulation promotes inflammatory 
mechanisms in NAFLD we focused our attention on the role of histidine-rich glycoprotein (HRGP), 
a hepatocyte-released mediator (i.e., hepatokine) that has been recently shown to support liver 
macrophage activation in experimental and clinical NAFLD/NASH.(32)      To investigate the possible 
hypoxia- and HIF-2α-dependent modulation of HRGP we employed HepG2 cells, which are known 
to rapidly respond to hypoxia with HIF-2α stabilization and the up-regulation of HIF-2α target 
genes.(28,33)   As shown in Figure 5A the incubation of HepG2 cells under hypoxic condition, which 
is known to rapidly promote the nuclear translocation of HIF-2α,(28) was associated to an 
appreciable increase in HRGP synthesis.   A very significant up-regulation of HRGP transcription 
was also observed in HepG2 transfected with an HIF-2α-containing, but not with an empty vector 
(Figure 5B), confirming a HIF-2α-dependent modulation of HRGP in liver cells.  According with the 
in vitro data, hepatic HRGP transcript levels increased in a time-dependent manner in control mice 
fed with CDAA diet in parallel with the upregulation of the expression of another HIF-2α-
dependent gene such as CXCR4 (Figure 5C). Conversely, HRGP up-regulation associated with 
NAFLD evolution was almost completely prevented at both mRNA and protein level in hHIF-2α-/- 
mice (Figure 5C,D).  The relationships between HIF-2α and HRGP were further confirmed by the 
evidence that HepG2 stably transfected to overexpress HIF-2α also overexpressed transcript levels 
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of other HIF-2α target genes such as CXCR4 and erythropoietin (Suppl. Figure 5 A,B) or, as 
previously reported,  SerpinB3. (28)  Moreover, HRGP transcript and protein levels were down-
regulated in HepG2 exposed to hypoxic conditions following efficient silencing for HIF-2α (Suppl. 
Figure 5 C,D). Immunohistochemistry performed on liver from mice fed with the CDAA diet 
confirmed that HRGP was selectively expressed by hepatocytes of control mice with 
steatohepatitis, but not in those from hHIF-2α-/- animals (Figure 5E).  HIF-2α and HRPG up-
regulation were unrelated to choline deficiency and were also observed in mice with NAFLD 
induced by administration in the drinking water of a high fat / fructose (HF/F) diet  (Suppl. Figure 6 
A-D).   Hepatocyte-derived HRGP has been recently shown to promote liver inflammation by 
stimulating M1 polarization of hepatic macrophages.(32)  In our hands, the impaired production of 
HRPG in mice receiving the CDAA diet decreased the liver infiltration by F4/80 positive 
macrophages as evidence by both immunohistochemistry (Figure 6A ) and flow cytometry (Suppl. 
Fig 7A).  Furthermore, the fraction of inflammatory Ly6Chigh hepatic macrophages and their 
capacity to produce IL-12 was significantly lower in hHIF-2α-/- mice as compared to control 
littermates (Figure 6B). Consistently the hepatic expression of M1 cyto/chemokines TNFα, IL-
12p40, CCL2 and CXCL10 (Suppl Figure 7B) and the serum levels of IL-12 were also significantly 
reduced in hHIF-2α-/- mice receiving the CDAA diet (Figure 6C) indicating a possible role of HRGP in 
the mechanisms by which the stimulation of HIF-2α in parenchymal cells supports pro-
inflammatory responses of hepatic macrophages.   
Finally, to further support the possible relevance of the relationships between HIF-2α and HRGP in 
the human disease, we analyzed for HIF-2α and HRGP immune-staining serial sections (4 μm thick) 
in our cohorts of NAFLD patients. Figure 7A shows that HRGP positivity was very low in sections 
from control livers. Conversely, in agreement with previous data,(32)  HPRG immune-staining was 
well evident and increased in liver sample from NAFLD patients irrespectively from the disease 
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evolution (Figure 7B,C) and co-localized with that of HIF-2α (Figure 7A).  Furthermore, we found a 
significant positive correlation between HIF-2α and HRGP mRNA levels in those patients of this 
cohort (n=19) for whom frozen liver specimens were available (Figure 7D).    
 
 
Discussion 
As mentioned in the introduction, hypoxia and HIFs have been proposed to play a role in the 
progression of CLD. (8-11) However, data concerning their role in the evolution of NAFLD are quite 
limited (10) and, more specifically, the contribution of HIF-2α has never been investigated in detail. 
In the present study we provide evidence that hepatocyte HIF-2α is up-regulated in either human 
or experimental NAFLD and we propose a mechanism by which HIF-2α activation in the liver 
parenchyma can contribute to the disease progression.  
To our knowledge, the present study is the first to report that HIF-2α is specifically overexpressed 
in hepatocytes during the development of human NAFLD.  In the majority of the liver biopsies 
from NAFLD patients a nuclear localization of HIF-2α  is also evident, indicating that, by forming 
heterodimer with either HIF-1β or HIF-2β, HIF-2α can act as a transcription factor. Interestingly,   
HIF-2α  activation is evident already in the early stage of the disease (F0-F1) and it is maintained 
up to more advanced (F3-F4) conditions of fibrosis/cirrhosis.  Similar findings  have been detected 
in murine models of NAFLD. In this setting, both HIF-2α and HIF-1α transcripts were up-regulated 
in mice with steatohepatitis, but only those of HIF-2α paralleled the disease progression. 
Altogether, these data suggest that HIF-dependent responses are an early event in NAFLD 
evolution and can be involved in the disease progression.  Hepatic hypoxia likely represents the 
most obvious cause for HIF-2α up-regulation in both human and experimental NAFLD.  In fact, 
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diffuse lobular staining with the hypoxia-sensitive dye pimonidazole has recently documented in 
mice with NAFLD.
 (21)  Nevertheless, we cannot exclude that hypoxia-independent mechanisms, as 
for instance oxidative stress, might also contribute to stimulate HIF-2α activity.
 (8-11)   
The actual relevance of HIF-2α in NAFLD progression has been mechanistically confirmed by 
inducing NAFLD with MCD or CDAA diets in mice carrying a hepatocyte specific deletion of HIF-2α 
(hHIF-2α-/- mice). We have observed that steatosis, parenchymal injury, inflammatory response 
and liver fibrosis are appreciably attenuated in these animals, as compared with control 
littermates. The decrease in fatty liver detected in hHIF-2α-/- mice is consistent with the 
observation that HIF-2α activation is per se capable to promote fatty liver by up-regulating genes 
involved in fatty acid synthesis/uptake and lipid storage and by down-regulating those involved in 
fatty acid catabolism.
 (18,19)  Accordingly,  in the CDAA diet model  transcript levels of SREBP1 and 
of FASN (Fatty Acid Synthase) were significantly reduced in hHIF-2α-/- mice vs related control 
littermates exposed to the same diet (Suppl. Figure 8). Moreover, by employing murine 
hepatocytes (AML12 line), we found that exposure of these cells to palmitic acid (i.e, a condition 
leading to lipid accumulation and mimicking “in vitro” lipotoxicity) resulted in a significant up-
regulation of both HIF-2α and HRGP protein levels (Suppl. Figure 9A) and of HRGP transcript levels 
(Suppl. Figure 9B), suggesting that also lipotoxicity may represent an additional condition leading 
to  HIF-2α and HRGP up-regulation.      
Furthermore, in a previous study using mice fed with a high fat diet the hepatocyte deletion of 
HIF-1α effectively prevented NAFLD associated liver fibrosis without interfering with fat 
accumulation. (21)  Interestingly, the same work also showed that hepatocyte HIF-1α deficiency 
moderately affected parenchymal damage and did not influenced the extent of lobular 
inflammation. (21)  This indicates that beside the action on steatosis, the activation of HIF-2α in 
hepatocytes has a key role in favoring NAFLD-associated cell injury and inflammatory responses.  
17 
 
To investigate whether hepatocyte HIF-2α might stimulate the production of mediators with pro-
inflammatory action, we focused the attention on the possible role of HRGP, a multifunctional 
hepatocyte-derived circulating protein, (34) that has been recently shown to be involved in 
modulating pro-inflammatory activity of macrophages in tumors as well during chronic liver injury. 
(32,35)  In particular,  Bartneck et al.
 (32)  have reported that HRGP deletion leads to a significant 
protection from liver injury and fibrosis in mice with MCD-induced NASH by down-modulating the 
recruitment of hepatic macrophages, and their M1 polarization.  In this setting, our data 
demonstrate an interplay between HIF-2α and HRGP during NAFLD evolution by showing that the 
lack of hepatocyte  HIF-2α prevents- HRGP up-regulation in mice fed with CDAA diet. Furthermore, 
HRGP staining of liver biopsies from NAFLD patients co-localizes with that of HIF-2α, while in the 
same subjects a positive linear correlation is evident between the HIF-2α and HRGP transcripts.  
These findings are supported by in vitro experiments employing HepG2 cells exposed to hypoxia or 
overexpressing HIF-2α that confirm the strict HIF-2α dependence of HRGP production.  
In line with the view that HIF-2α deficiency can reduce hepatic inflammation by preventing HRGP-
mediated support to M1 activation of liver macrophages, we have observed that the liver 
expression of M1 markers TNF-α, IL-12and CXCL10 is blunted in hHIF-2α-/- mice with NAFLD. 
Moreover, flow cytometry reveals that the prevalence of pro-inflammatory Ly6Chigh hepatic 
macrophages and their capacity to produce IL-12 are lowered in hHIF-2α-/- mice fed the CDAA diet.   
HIF-2α influence on macrophage responses is of potential general relevance since it is well known 
that the polarization of hepatic macrophages is a crucial determinant for the progression of CLDs. 
(36) In particular,  macrophage M1 shift has been reported to correlate with the severity of both 
alcoholic and non-alcoholic liver disease. (37,38) Accordingly, M2 skewing is associated with a more 
favorable histology and fewer hepatic lesions in patients with ethanol-related CLD (37) as well as in 
HRGP-/-  mice exposed to chronic liver injury. (32) 
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The involvement of HRGP in mediating the effects of HIF-2α activation during NAFLD progression 
does not rule out the possible involvement of other mediators.   We have previously reported that 
HIF-2α activation in human liver cancer cells up-regulates Serpin B3 and this latter contributes to 
the development of fibrosis during CLD by sustaining the most relevant profibrogenic responses by 
activated stellated cells.(28,30) Unfortunately, at difference of humans, SerpinB3 is virtually 
undetectable in murine livers during CLD, thus in the present study we did not have the possibility 
to evaluate its contribution to NAFLD progression.    However, based on the association between 
circulating levels of Serpin B3 and the risk of fibrosis in patients with chronic hepatitis C,(39) a 
possible role of Serpin B3 in the evolution of human NAFLD cannot be excluded.  
In conclusion, data presented indicate that hepatocyte HIF-2α activation during the evolution of 
human and murine NAFLD has a role in the disease progression by mediating the up-regulation of 
HRGP expression that, in turn critically influence the severity of steatohepatitis and fibrogenesis. 
These findings point HIF-2α and HIF-2α-dependent genes as putative targets for future therapeutic 
strategies in NAFLD, a disease that, at present, has no validated therapy.        
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Figure Legends  
Figure 1. Expression of HIF-2α in human liver disease. Immunohistochemistry analysis of HIF-2α  
in paraffin-embedded human liver specimens from NAFLD patients (n = 27)  with different degrees 
of liver fibrosis (F0-F4) (A). Control liver refer to surgical resections for hepatic metastasis of colon 
carcinoma (magnification 20X, 40X, 100X). HIF-2α expression was semi-quantitatively scored 
blinded, by a pathologist. P < 0.05 (Mann-Whitney’s U test). (B). 
Figure 2. Liver injury and inflammatory markers in hHIF2α -/- and control mice with NAFLD 
induced by feeding a MCD diet. hHIF2α-/- and wild type littermates (LM) were fed a MCD diet for 4 
weeks and the following parameters were evaluated:  (A-C) Parenchymal injury and liver steatosis, 
as evaluated by measuring (A) serum levels of alanine (ALT), (B) hepatic TG content or, 
morphologically, by hematoxylin/eosin staining (magnification 10X) (C); (D) Liver expression of 
inflammatory markers TNF-α, CD11b and CCL2, as evaluated by quantitative real-time PCR (Q-
PCR).   The mRNA values are expressed as fold increase over control values after normalization to 
the β-actin gene expression and are means ± SD of 6-8 animals per group. The boxes include the 
values within 25th and 75th percentile, while the horizontal bars represent the medians. The 
extremities of the vertical bars (10th-90th percentile) comprise the eighty percent of the values. 
Statistical differences were assessed by one-way ANOVA test with Tukey's correction for multiple 
comparisons.  
Figure 3.  Liver injury in hHIF2α-/- and control mice fed with a CDAA diet. hHIF2α-/-  and wild type 
littermates (LM) were fed CDAA diet for 12 or 24 weeks and the following parameters were 
evaluated:  Parenchymal injury, as evaluated by measuring the serum levels of alanine (ALT) (A)  or 
hepatic TG content (B);  Body weight change (C) and plasma glucose concentration (D). Liver 
morphology in mice exposed to CDAA diet was evaluated by hematoxylin/eosin staining 
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(magnification 10X) (E). The values are means ± SD and refer to 6-8 animals per group. Statistical 
differences were assessed by one-way ANOVA test with Tukey's correction for multiple 
comparisons.  
Figure 4. Liver fibrosis “in vivo” in hHIF-2α-/- mice vs LM mice fed with CDAA diet. Liver fibrosis 
was evaluated morphologically in hHIF-2α-/- mice and wild type littermates (LM) mice following 12 
or 24 weeks on the CDAA or control CSAA diets by Sirius red staining (A) and 
immunohistochemistry for α-SMA (D). Original magnification as indicated.  ImageJ software 
analysis was performed for Sirius red staining to evaluate the amount of fibrosis (B).  Analysis by 
quantitative real-time PCR (Q-PCR) of transcript levels of pro-fibrogenic genes collagen 1A1, 
αSMA, TGFβ1 in the different experimental groups (C). The values are means ± SD and refer to 6-8 
animals per group. Statistical differences were assessed by one-way ANOVA test with Tukey's 
correction for multiple comparisons.  
Figure 5. Modulatory effect of HIF2α on HRGP. Western blotting analysis of HIF2α and HRGP 
levels in HepG2 cells exposed to hypoxic conditions (A). Q-PCR analysis of HRGP transcript in 
control HepG2 cells (HepG2 C: not transfected; EV: transfected with empty vector) or HepG2 cells 
stably transfected to over-express HIF-2α (B). Data in graphs are expressed as means ± SEM. qPCR 
analysis of HRGP and CXCR4 transcripts in wild type littermates (LM) or hHIF-2α-/- mice fed with 
the control diet (CSAA) or with the CDAA diet for 12 and 24 weeks (C). Hepatic mRNAs was as fold 
increase over control values after normalization to the β-actin gene expression. The values are 
means ± SD and refer to 6-8 animals per group. Statistical differences were assessed by one-way 
ANOVA test with Tukey's correction for multiple comparisons). Western blotting analysis of HRGP 
levels in liver of hHIF-2α-/- and littermate mice fed with CDAA diet for 24 weeks (D). Histograms 
report densitometric analyses normalized for the relative GAPDH content. Localization of HRGP 
expression by IHC in the livers of wild type littermates (LM) or hHIF-2α-/- CDAA or CSAA fed 
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animals. Original magnification as indicated. ImageJ software analysis was performed for 
quantification of HRGP staining (E). Data are expressed as means ± SD. 
Figure 6.   Inflammatory markers in hHIF-2α-/- and control mice fed with a CDAA diet.  hHIF-2α-/- 
and wild type littermates (LM) mice were fed with a CDAA diet or CSAA diet for 12 or 24 weeks 
and the detection of macrophages positive for F4/80 was evaluated by IHC (original magnification 
as indicated). ImageJ software analysis was performed for quantification of F4/80 staining (A). 
Data are expressed as means ± SD. Hepatic myeloid cells were isolated from livers of either hHIF-
2α-/- mice and wild type littermates (LM) fed with the CDAA diet analyzed by flow cytometry for 
Ly6C and IL expression in Cd11b/F4-80-positive liver macrophages. (B) Data are expressed as 
means ± SD. Circulating IL-12 levels were determined by ELISA assay (C). Values refer to 6-8-10 
animals per group; boxes include the values within 25th and 75th percentile, whereas horizontal 
bars represent the medians. The extremities of the vertical bars (10th-90th percentile) comprise 
80% of the values. Statistical differences were assessed by one-way ANOVA test with Tukey's 
correction for multiple comparisons. 
Figure 7. HRGP expression in human livers with NASH. HRGP detection by IHC in liver specimens 
from NASH patients (n =27) with different degrees of liver fibrosis (F0-F4, NAS 2-6). Control liver 
sample refer to surgical resections for hepatic metastasis of colon carcinoma. Original 
magnification as indicated. ImageJ software analysis was performed for quantification of HRGP 
staining (A). Data are expressed as means ± SD. HRGP expression was semi-quantitatively scored 
by a pathologist. P value were calculated with Mann-Whitney’s U test (B). Relationship between 
HRGP and HIF2α mRNA in human NASH patients (F0-F4, NAS 2-6) (C). The values represent the 
relative mRNA content. The correlation analysis was performed with Spearman r test. 
 
27 
 
 
 
28 
 
 
29 
 
 
 
 
30 
 
 
 
31 
 
 
 
32 
 
 
 
33 
 
 
 
34 
 
 
 
 
35 
 
 
 
 
 
 
36 
 
 
 
 
37 
 
 
38 
 
 
39 
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Supplementary material and methods 
Materials: 
Enhanced chemiluminescence (ECL) reagents and nitrocellulose membranes (Hybond-C extra  
were from Amersham Pharmacia Biotech Inc. (Piscataway, NJ, USA).   Polyclonal antibody against 
HIF-2α (NB100-122) was from Novus Biologicals (Cambridge, UK); GAPDH (sc-20357) was from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA); mouse HRG (AF1905) was from R&D systems 
(Minneapolis, MN, USA) human HRG used for Western Blot detection (ab67807) was from Abcam 
(Cambridge, UK) and human HRG for immunohistochemistry experiments (HPA050269) was from 
Sigma (Sigma-Aldrich, St. Louis, MO, USA). Monoclonal antibodies for α-tubulin (T6074) and β-
actin (A5441) were from Sigma (Sigma Aldrich Spa, Milan, Italy). Monoclonal antibodies against 
F4/80 for immunohistochemistry (14/4801/82) was from eBioscences (Affymetrix, St Clara, CA, 
USA) and α-SMA (M0851) was from DAKO (Agilent, St Clara, CA, USA). Lipofectamine 2000 
(Invitrogen-Life Technologies), Plasmid DNA purification NucleoBond XtraMIDI (Macherey-Nagel, 
Germany), pCMV6-Entry vectors (Origene, Rockville, MD). RNA interference experiments to 
knockdown HIF-2α expression in HepG2 cells were performed using siRNA duplex (Qiagen Italia, 
Milano, Italy). 
Immunohistochemistry, Sirius Red staining and histomorphometric analysis: 
Paraffin-embedded human liver biopsies and/or murine liver specimens used in this study were 
immuno-stained as previously reported (1,2), and more details are reported in using polyclonal 
anti-HIF-2α antibody (dil. 1:100 v/v), polyclonal anti-HRGP antibody (dil. 1:50, v/v),  monoclonal 
anti-α-SMA antibody (dil. 1:400, v/v) or F4-80 monocloclonal antibodies (dilution 1:1000, v/v).     
Collagen deposition was evidenced by Picro-Sirius Red staining as previously described, (30,31)  
and quantification of fibrosis in the murine liver was performed by histo-morphometric analysis 
using a digital camera and a bright field microscope to collect images that were then analyzed by 
employing the ImageJ software. (3) Hematoxilin/eosin stained mice liver sections were scored 
blind for steatosis and lobular inflammation. (4)    
In vitro experiments and cell culture conditions:   
In this study HepG2 cells (American Type Culture Collection, USA) were used and maintained in 
Dulbecco's modified Eagle's medium supplemented with 10% fetal-bovine serum, 100 U/ml 
penicillin, 100 μg/ml streptomycin and 25 μg/ml amphotericin-B, as previously reported. (1)  In 
order to evaluate the HRGP protein levels under hypoxia condition, normal HepG2 cells were 
incubated in strictly controlled hypoxic conditions (3% O2) up to 72 hours.  
The pCMV6-based mammalian expression vectors, empty (used as a control) and encoding HIF-2α 
(OriGene, Rockville, MD), were used in order to generate and select HepG2 cells stably 
overexpressing HIRF-2α. (28) HepG2 cells were seeded and then transfected 24 hr later with 10 μg 
of each vector using Lipofectamine 2000 (Invitrogen, Carlsbad, CA). HIF-2α expression of the 
generated stable transfectants was carefully characterized, after which the cell lines carrying the 
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empty vector (EV) and overexpressing HIF-2α (HepG2 Hif-2α) were then used for the experiment 
described. 
RNA interference experiments to knockdown HIF-2α expression in HepG2 cells were performed 
using siRNA duplex  as previously described [1].  The following target sequence was used: 
-HIF-2α: 5′-CCCGGATAGACTTATTGCCAA-3′. 
The siRNA and related non-silencing controls were transfected in HepG2 cells with lipofectamine 
2000 transfection reagent according to manufacturer's instructions up to 72 hrs. Transfected cells 
in fresh medium were then exposed for further 48 hrs to the desired experimental conditions and 
then harvested for sample preparation. 
Western blot analysis: 
Total cell lysates, obtained as previously described, (1,3)  were subjected to sodium dodecyl 
sulfate-polyacrylamide gel-electrophoresis on 12%, 10% or 7.5% acrylamide gels, incubated with 
desired primary antibodies, then with peroxidase-conjugated anti-mouse or anti-rabbit 
immunoglobulins in Tris-buffered saline-Tween containing 2% (w/v) non-fat dry milk and finally 
developed with the ECL reagents according to manufacturer’s instructions. Sample loading was 
evaluated by reblotting the same membrane with antibodies raised against GAPDH, α-tubulin and 
β-actin. 
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Supplementary Tables  
 
Supplementary Table 1 
 
Clinical and biochemical characterization of NAFLD patients investigated. 
 
 
 
Demographic Data 
Patients Number (Male/Female) 27 (15/12) 
Age (Years) 48 (23-70) 
BMI 30.2 (22.3-39.6) 
 Biochemical Data 
HOMA-IR (n.v. <3) 3.7 (0.8-14.1) 
AST (U/L– n.v. 5–40) 33.5 (16-93) 
ALT (U/L n.v. 5–40) 44.1 (9-82) 
-GT  (U/L n.v. 5–45) 54.0 (11-525) 
Fasting Glucose (mg/dL n.v. <100) 94.6 (72-197) 
 Histological Data 
Steatosis score 2 (0-3) 
Inflammation score 1 (0-2) 
Ballooning score 1 (0-2) 
Fibrosis score 2 (0-4) 
NAS score 4 (1-6) 
 
The values are expressed as median and inter-quartile range (IQR). For histological scores the 
range of variability is included.   
 
BMI, body mass index; AST, alanine aminotransferase; ALT, aspartate aminotransferase; γ-GT, 
gamma-glutamyl transpeptidase;  HOMA-IR, homeostatic model assessment-insulin resistance; ISI, 
insulin sensitivity index; n.v., normal value 
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Supplementary Table 2 
                                      Oligonucleotide sequences of primers used for Q-PCR. 
 
Gene Primers 
 
HIF1-α (mouse) 
(FW) 5- TCAAGTTCAGCAACGTGGAAG -3 
(RV)  5- TATCGAGGCTGTGTCGACTG -3 
 
HIF2-α (mouse) 
(FW) 5- CTAAGTGGCCTGTGGGTGAT -3 
(RV)  5- GTGTCTTGGAAGGCTTGCTC-3 
 
VEGF-A (mouse) 
(FW) 5- CAGGCTGCTGTAACGATGAA-3  
(RV)  5- TTTCTTGCGCTTTCGTTTTT -3 
 
TGF-β (mouse) 
(FW) 5- GGACTCTCCACCTGCAAGAC -3  
(RV)  5- GACTGGCGAGCCTTAGTTTG -3 
 
αSMA (mouse) 
(FW) 5- CTGACAGAGGCACCACTGAA -3  
(RV)  5- CATCTCCAGAGTCCAGCACA -3 
 
COL1A1 (mouse) 
(FW) 5- GAGCGGAGAGTACTGGATCG -3  
(RV)  5- GTTCGGGCTGATGTACCAGT -3 
 
TIMP1 (mouse) 
(FW) 5- ATTCAAGGCTGTGGGAAATG -3  
(RV)  5- CTCAGAGTACGCCAGGGAAC -3 
 
β-ACTIN (mouse) 
(FW) 5-AGCCATGTACGTAGCCATCC -3  
(RV)  5- CTCTCAGCTGTGGTGGTGAA -3 
 
HIF2-α (human) 
(FW) 5- CGCTAGACTCCGAGAACAT -3  
(RV)  5- GGCTTGAACAGGGATTCAGT -3 
 
β-ACTIN (human) 
(FW) 5- AGAGCTACGAGCTGCCTGAC -3  
(RV)  5- GGATGCCACAGGACTGGA -3 
 
HRG (human) 
(FW) 5- GCCCGAAAAACCTTGTCATA -3 
(RV)  5- CTAGATCCATGGGGCTTGAA -3  
CXCR4 (mouse) (FW) 5- TGGAACCGATCAGTGTGAGT -3 
(RV)  5- TTGCCGACTATGCCAGTCAA -3 
CXCR4 (human) (FW) 5- TCCATTCCTTTGCCTCTTTTGC -3 
(RV)  5- ACGGAAACAGGGTTCCTTCAT -3 
FASN (mouse) (FW) 5- TGGGTTCTAGCCAGCAGAGT -3 
(RV)  5- ACCACCAGAGACCGTTATGC -3 
SREBP1 (mouse) (FW) 5- GATCAAAGAGGAGCCAGTGC -3 
(RV)  5- TAGATGGTGGCTGCTGAGTG -3 
EPO (human) (FW) 5- GAGCCCAGAAGGAAGCCATC -3 
(RV)  5- GCGGAAAGTGTCAGCAGTGA -3 
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Suppl. Fig. 1. Expression of HIF-2α  in mice liver. Immunohistochemistry analysis for HIF-2α and α-
smooth muscle actin (α-SMA) in liver specimens from wild type mice fed with control (A) or MCD 
diet (8 weeks) (B). Original magnification as indicated. Liver expression of HIF-2α (C) and HIF-1α 
(D), evaluated by quantitative real-time PCR (Q-PCR) in MCD fed mice (4 and 8 weeks).  
Parenchymal injury and steatosis, estimated by measuring the circulating levels of alanine (ALT) (E) 
and hepatic TG content (F) are reported in MCD fed mice. The mRNA values are expressed as fold 
increase over control values after normalization to the β-actin gene expression. The data are 
means ± SD of 5-7 animals per group. Boxes include the values within 25th and 75th percentile, 
whereas horizontal bars represent the medians. The extremities of the vertical bars (10th-90th 
percentile) comprise 80% of the values. Statistical differences were assessed by one-way ANOVA 
test with Tukey's correction for multiple comparisons. 
 
E F 
Morello et al. Suppl. Figure 1C-F 
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Suppl. Fig. 2.  HIFs and VEGF gene expression in mice carrying hepatocyte-specific deletion of 
HIF-2α. Gene expression of HIF-2α (A), HIF-1α (B) and VEGF (C) evaluated by quantitative real-time 
PCR (Q-PCR) in livers of wild type littermates (LM) and hHIF2α-/- mice fed with the MCD diet for 4 
weeks. The mRNA values are expressed as fold increase over control values after normalization to 
the β-actin gene expression. The data are means ± SD of 5-7 animals per group. Boxes include the 
values within 25th and 75th percentile, whereas horizontal bars represent the medians. The 
extremities of the vertical bars (10th-90th percentile) comprise 80% of the values. Statistical 
differences were assessed by one-way ANOVA test with Tukey's correction for multiple 
comparisons. Western blot analysis of HIF-2α protein levels was performed on total liver extracts 
obtained from either LM and hHIF2α -/- mice fed MCD diet for 8 weeks (D).  
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Suppl. Fig. 3. Expression of HIF-2α  in mice liver. Immunohistochemistry analysis for HIF-2α  in the livers of 
wild type littermates (LM) or hHIF-2α
-/-
 CDAA or CSAA fed animals (12 and 24 weeks) (A). Original 
magnification as indicated. 
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        Morello E et al. Suppl. Figure 4 A,B 
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                   Morello E et al. Suppl. Figure 4 C 
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                       Morello E et al. Suppl. Figure 4 D  
Suppl. Fig. 4 A-D.  Effect on liver fibrosis  of hepatocyte deletion of HIF-2α. hHIF-2α-/-  mice and 
wild type littermates (LM) were fed with MCD diet for 8 weeks. Liver fibrosis was morphologically 
evaluated by Sirius red staining (A). Original magnification as indicated.  ImageJ software analysis 
was performed for Sirius red staining (B) to evaluate the amount of fibrosis. 
Immunohistochemistry for α-SMA (C) in the same animals.  Data in graphs are expressed as 
means ± SEM.  Analysis by quantitative real-time PCR (Q-PCR) of transcript levels of pro-fibrogenic 
genes pro-collagen 1A1, αSMA, TGFβ1 and TIMP1 in the different experimental groups (D). The 
mRNA values are expressed as fold increase over control values after normalization to the β-actin 
gene expression. The data are means ± SD of 6-7 animals per group. Boxes include the values 
within 25th and 75th percentile, whereas horizontal bars represent the medians. The extremities 
of the vertical bars (10th-90th percentile) comprise 80% of the values. Statistical differences were 
assessed by one-way ANOVA test with Tukey's correction for multiple comparisons. 
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Suppl. Fig. 5. Direct relationships between HIF2α and HRGP expression. Western blotting analysis 
of HIF-2α levels in control HepG2 cells or HepG2 cells stably transfected to over-express HIF-2α 
exposed to hypoxic conditions (H/C: not transfected; H/EV: transfected with empty vector; H/HIF-
2α: overexpressing HIF-2α ) (A). Q-PCR analysis of HIF-2α and related targets transcript, including 
CXCR4 and erythropoietin (EPO) in control HepG2 cells (HepG2 C: not transfected; EV: transfected 
with empty vector) or HepG2 cells stably transfected to over-express HIF-2α (B). Q-PCR (C) and WB 
analysis (D) of HRGP transcript and protein levels  in untreated HepG2 in normoxic conditions (C) 
or in HepG2 exposed for three hours to hypoxic conditions only (C hyp) as previously described (1) 
or  in HepG2 exposed to hypoxia following silencing for HIF-2α with a specific siRNA (siRNA-HIF2α) 
or treatment with a non-silencing siRNA (NsC) (C,D). WB analysis is offered also for HIF2α protein 
levels (D). Data in graphs are expressed as means ± SEM. Statistical differences were assessed by 
one-way ANOVA test with Tukey's correction for multiple comparisons. 
C 
D 
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Suppl. Fig. 6. HIF-2α and HRGP  expression in mice fed on High Fat / Fructose diet.  C57BL/6 wild 
type mice were fed for 24 weeks with an high fat diet (58% of energy derived from fat, 18% from 
protein, and 24% from carbohydrates; 5.6 kcal/g) (Envigo RMS, S Pietro al Natisone, Italy) 
supplemented with 15% fructose (wt/v) in the drinking water. Liver morphology in mice exposed to 
HF/fructose mice diet or related control diet was evaluated by hematoxylin/eosin staining 
(magnification 10X) (A). Parenchymal injury was evaluated by measuring the serum levels of 
alanine (ALT) and pro-inflammatory citokynes mRNA levels (B). Elevation of both HIF-2α and HRGP 
protein levels was detected by Western blotting (C) and immune-histochemistry (IHC) analyses 
(magnification 20X) (D). The mRNA values are expressed as fold increase over control values after 
normalization to the β-actin gene expression and are means ± SD of 6-8 animals per group. The 
boxes include the values within 25
th
 and 75
th
 percentile, while the horizontal bars represent the 
medians. The extremities of the vertical bars (10
th
-90
th
 percentile) comprise the eighty percent of 
the values. Statistical differences were assessed by one-way ANOVA test with Tukey's correction for 
multiple comparisons. 
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Suppl. Fig. 7. HIF2α-deficiency regulates macrophage infiltration. Hepatic myeloid cells were 
isolated from livers of either hHIF-2α
-/-
 mice and wild type littermates (LM) fed with the CDAA diet 
analyzed by flow cytometry for Cd11b expression in CD45/F4-80-positive liver macrophages (A). 
Liver expression of inflammatory markers IL-12p40, TNF-α, CCL2 and CXCL10 was evaluated by 
quantitative real-time PCR (Q-PCR). The mRNA values are expressed as fold increase over control 
values after normalization to the β-actin gene expression and are means ± SD of 6-8 animals per 
group  (B).  Statistical differences were assessed by one-way ANOVA test with Tukey's correction for 
multiple comparisons. 
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Suppl. Fig. 8. HIF-2α modulates lipid homeostatic genes  in the liver. qPCR analysis of sterol 
regulatory element binding factor -1 (SREBP1) and fatty acid synthase (FASN) in livers from hHIF-
2α-/- mice vs related control littermates exposed to CDAA or CSAA diet. The mRNA values are 
expressed after normalization to the β-actin gene expression and are means ± SD of 6-8 animals 
per group. The boxes include the values within 25
th
 and 75
th
 percentile, while the horizontal bars 
represent the medians. The extremities of the vertical bars (10
th
-90
th
 percentile) comprise the 
eighty percent of the values. Statistical differences were assessed by one-way ANOVA test with 
Tukey's correction for multiple comparisons.  
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Suppl. Fig. 9. Murine hepatocytes treated with palmitic acid. Western blotting analysis of both 
HIF-2α and HRGP levels in AML12 cell line treated with palmitic acid 0,25mM up to 24hrs (A). Q-
PCR analysis of HRGP in AML12 hepatocytes treated with palmitic acid 0,25mM up to 24hrs (B). 
Data in graphs are expressed as means ± SEM. Statistical differences were assessed by one-way 
ANOVA test with Tukey's correction for multiple comparisons. 
59 
 
 
References for Supplementary Material 
1. Cannito S, Turato C, Paternostro C, Biasiolo A, Colombatto S, Cambieri I, et al.  Hypoxia up-
regulates SERPINB3 through HIF-2α in human liver cancer cells. Oncotarget 2015; 6:2206-2221. 
2. Novo, E, Busletta C, Valfrè di Bonzo L, Povero D, Paternostro C, Mareschi K, et al. Intracellular 
reactive oxygen species are required for directional migration of resident and bone marrow-
derived hepatic pro-fibrogenic cells. J Hepatol 2011;54:964-974. 
3. Novo E, Villano G, Turato C, Cannito S, Paternostro C, Busletta C, et al. SerpinB3 promotes pro-
fibrogenic responses in activated hepatic stellate cells. Scientific Reports 2017;7(1):3420.  
4. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and 
validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology  
2005;41:1313-1321. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
